Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Inclusion criteria: * .Diagnosis of type 2 diabetes mellitus prior to informed consent * Male and female patients, on diet and exercise regimen, who are pre-treated with one of the following oral antidiabetic drugs: sulfonylurea, glinide, biguanide, Alpha-glucosidase inhibitor (a-GI), dipeptidyl peptidase-IV (DPP-IV) inhibitor or thiazolidinedione * glycosylated haemoglobin (HbA1c) at Visit 1: \>=7.0 to =\<10.0% (national glycohemoglobin standardization program) Exclusion criteria: * Uncontrolled hyperglycaemia with a glucose level \>240 mg/dL (\>13.3 mmol/L) * Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent * Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)